Business
CytoMed Therapeutics to Ring Nasdaq Closing Bell
SINGAPORE, May 11, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited ("CytoMed" or the "Company") (Nasdaq: GDTC), a biopharmaceutical company focused on
About this update from Cytomed Therapeutics Limited
[{"type":"text","content":"SINGAPORE, May 11, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (\"CytoMed\" or the \"Company\") (Nasdaq: GDTC), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, will commemorate the closing of its initial public offering (\"IPO\") on April 18, 2023, by ringing the closing bell at Nasdaq this afternoon.\n\n \n \n \n \n \n \n\n \nCytoMed was formed in 2018, when it was spun off from Singapore's leading public Research and Development agency, the Agency for Science, Technology, and Research, or A*STAR, with a mission to produce more effective and affordable cellular immunotherapies for a wide range of solid and blood-based cancers. Cellular immunotherapies harness the immune system's ability to target and destroy cancer cells and offer a potentially life-changing option for patients where traditional approaches such as chemotherapy and radiation have failed. These therapies have historically been extremely expensive and complex to manufacture and administer. They have been designed on a patient-by-patient basis using the specific cancer patient's own blood cells and typically only target the receptors of one specific cancer cell.\nCytoMed's manufacturing process utilizes noninvasive blood draws from healthy donors to create scalable, \"off-the-shelf\" therapies that are allogenic, naturally expressing an array of built-in receptors to recognize a multitude of cancers that are expected to be effective for a spectrum of patients without the need for expensive matching. The standardized process and broad application should allow for a more affordable treatment option for patients and may also reduce the risk of \"on-target, off-cancer\" side effects. The leading therapeutic clinical candidate leverages chimeric antigen receptor (CAR) gamma delta t cells and has been engineered to target cancers in a broad range of blood-based and solid cancers. Currently available chimeric antigen receptor t-cells (CAR T-Cell) therapies are being used to treat hematologic cancers but have not yet been successfully adapted for the treatment of solid cancers. CytoMed hopes to be able to change that.\n\"Our ability to drive innovation is a testament to Singapore's support for cutting-edge life science research, the resour...